CanScan | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

72 results for “CanScan”

Trials

View all 56 →

CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management

10,000 participants · First posted Feb 3, 2025

Feasibility Study of Dialysis Clinic Semi-Autonomous Ultrasound Scanning Using the Vexev Ultrasound Imaging System for Arteriovenous Fistula Mapping Examinations. The CANSCAN Trial.

120 participants · First posted Nov 15, 2024

CanCan Body Composition Study

40 participants · First posted Dec 26, 2025

Drugs

FAP-CAR-T cells (Capstan Therapeutics)

ASPA gene modulator (AAV, Canavan disease)

rAAV-based gene therapy (Canavan Disease) (Bamboo Therapeutics)

News

View all 12 →

Geneseeq Secures FDA 510(k) Clearance for Comprehensive 425-Gene Tumor Profiling Assay

Geneseeq's PanTRKare™ Receives NMPA Approval as China's First NGS-Based Pan-Solid Tumor Companion Diagnostic for NTRK Gene Fusions

Myrtelle's rAAV-Olig001-ASPA Gene Therapy Shows Promise in Canavan Disease Trial

Page 1 of 8